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Abstract  
The cucurbituril family of drug delivery vehicles have been examined for their tissue specific 
toxicity using ex vivo models. Cucurbit[6]uril (CB[6]), cucurbit[7]uril (CB[7]) and the linear 
cucurbituril-derivative Motor2 were examined for their neuro-, myo- and cardiotoxic activity 
and compared with ȕ-cyclodextrin. The protective effect of drug encapsulation by CB[7] was 
also examined on the platinum-based anticancer drug cisplatin. The results show that none of 
the cucurbiturils have statistically measurable neurotoxicity as measured using mouse sciatic 
nerve compound action potential.  Cucurbituril myotoxicity was measured by nerve-muscle 
force of contraction through chemical and electrical stimulation. Motor2 was found to display 
no myotoxicity, whereas both CB[6] and CB[7] showed myotoxic activity via a presynaptic 
effect. Finally, cardiotoxicity, which was measured by changes in the rate and force of right 
and left atria contraction, was observed for all three cucurbiturils. Free cisplatin displays 
neuro-, myo- and cardiotoxic activity, consistent with the side-effects seen in the clinic. 
Whilst &%>@KDGQRHIIHFWRQWKHOHYHORIFLVSODWLQ¶VQHXURWR[LFDFWLYLW\ drug encapsulation 
within the macrocycle had a marked reduction in ERWKWKHGUXJ¶Vmyo- and cardiotoxic 
activity. Overall the results are consistent with the relative lack of toxicity displayed by these 
macrocycles in whole animal acute systemic toxicity studies and indicate continued potential 
of cucurbiturils as drug delivery vehicles for the reduction of the side effects associated with 
platinum-based chemotherapy. 
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Introduction  
Macrocycles are an important class of delivery vehicle that have the ability to form a range of 
host-guest complexes with drugs. This encapsulation can provide many benefits including: 
increased drug solubility, physical and chemical stability, taste masking, a reduction of drugs¶ 
toxic side effects and modulation of their cell uptake.1 Furthermore, encapsulation can also 
provide controlled release ensuring that a high and consistent therapeutic concentration is 
available for a longer period of time compared to the free drug, thus increasing its 
bioavailability.   
 
Although a number of macrocycles have already shown potential as delivery vehicles, there is 
still an increasing demand for a larger and more diverse selection as no one host is suitable 
for every drug. The cucurbit[n]urils (CB[n], where n represents the number of glycoluril 
units),2, 3 cyclodextrins,4, 5 and calixarenes6, 7 are the three main types of macrocycles that 
have been examined as drug delivery vehicles.  
 
Cucurbit[n]urils, (Figure 1) are named for their resemblance to the shape of a pumpkin 
(cucurbitaceae). Native CB[n]s are synthesised from an acid-catalysed condensation reaction 
and are structurally made up of repeating glycoluril units linked by methylene bridges.8 To 
date the CB[n] family consists of CB[5-8], CB[10] and CB[14].8-10 All of the CB[n] 
homologues (except CB[14]) share a common height of 9.1 Å but differ in the diameter of 
their cavities. Cucurbit[14]uril does not have a normal cavity as a consequence of a twist in 
its structure, but instead adopts a figure-of-eight conformation.10 Each native CB[n] (except 
CB[14]) contains two hydrophilic carbonyl portals and a hydrophobic interior and drug 
encapsulation is achieved via ion-dipole or hydrogen bonds to the CB[n] portals and through 
the hydrophobic effect upon CB[n]-drug host-guest complex formation.11 Cucurbit[6]uril, 
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CB[7] and CB[8] are most commonly used in drug delivery as the cavity of CB[5] is too 
small for drug incorporation and the cavity of CB[10] is too large for strong drug binding.1  
 
Since the structural determination of CB[6] over three decades ago, several new cucurbituril 
derivatives have been developed, including Motor2 (Figure 1). Whilst Motor2 is not a 
macrocycle but a linear chain, in solution it is able to fold to create a cavity similar to that of 
the native cucurbit[n]urils. The anionic charges of Motor2 means it is considerably more 
water soluble (18 mM in pure water) than the native cucurbiturils, and forms stronger bonds 
with cationic drugs through electrostatic interactions.12  
 
The benefits of encapsulation by the CB[n]s are best demonstrated by the platinum-based 
drugs. In a recent study, it was shown that when encapsulated by CB[7], the anticancer drug 
cisplatin was able to overcome its own acquired resistance in an in vivo human tumour 
xenograft model via a pharmacokinetic effect.13 Furthermore, encapsulation of the 
multinuclear platinum-based drug BBR3571 by CB[7] increased its maximum tolerated dose 
by 70% with the encapsulated complex being just as anticancer active as the free drug.14 
These results suggest a promising outlook for the use of CB[n] as drug delivery vehicles. 
Before CB[n]s can be approved for use in drug delivery; however, they must not only 
demonstrate that they are able to increase the efficacy of the encapsulated drugs and/or 
decrease their associated side effects but that they are also safe in terms of their systemic and 
organ specific toxicities.  
 
 
 
 
 5 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1. The chemical structures of the macrocycles (a) cucurbit[n]uril, (b) n-cyclodextrin, 
and (c) Motor2.  
 
Various in vitro and in vivo studies have thus far indicated that CB[n]s and their derivatives 
are both inert and non-toxic. Several studies have shown that at concentrations of up to 1 
mM,15, 16 CB[7] displays no cytotoxic activity in a range of human and animal cell lines. 
When administered in vivo CB[7] has a maximum tolerated dose (MTD) of 250 mg/kg;  
intravenous injection of CB[n]s is limited more by their solubility rather than their side-
effects. When a mixture of CB[6]/CB[8] was administered orally the MTD increased to 600 
mg/kg.17 Overall they show little sign of acute systemic toxicity. Motor2, has also been 
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shown to be relatively non-toxic in human liver and kidney cells at concentrations up to 10 
mM and when administered intravenously shows no systemic toxic effects at doses of up to 
1,230 mg/kg.12 
 
In comparison, cyclodextrins, which are already approved for use in drug formulation, have 
been shown to be relatively non-toxic with lethal doses (LD50) in rats and mice between 0.3 
to 18.8 g/kg depending on the type of cyclodextrin and the route of administration.18 ȕ-
cyclodextrin, which is composed of seven glucopyranose units, is however known to be 
nephrotoxic when delivered intravenously.18  
 
A limitation to these in vitro and in vivo systemic approaches is that little information can be 
gathered on the toxicity of cucurbiturils to specific organs and the mechanism by which they 
do so. Therefore, the use of ex vivo toxicological models, in which the toxicity of the test 
compound is determined on intact whole tissue, can provide crucial and reliable predictions 
of the organ toxicity of CB[n]s in the human body.19, 20  
 
In this paper we report the use of ex vivo electrophysiological models to study the neurotoxic, 
myotoxic and cardiotoxic activity of native CB[n]s and Motor2 compared with ȕ-
cyclodextrin. In addition, the effect of CB[7] on the organ specific toxicity of cisplatin is 
examined.   
 
Materials and Methods  
%$/%&PLFHDQG6SUDJXH'DZOH\UDWVZHUHREWDLQHGIURP6WUDWKFO\GH8QLYHUVLW\¶VLQ
house breeding colonies that were originally sourced from Harlan, UK. Baby chicks were 
supplied from a breeding hatchery in Scotland (non-schedule 2 supplier). All animals were 
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euthanized in compliance of the Code of Practice for the Humane Killing of Animals issued 
by the UK Home Office and in accordance with ethical guidelines of the Strathclyde Institute 
of Pharmacy and Biomedical Sciences. &LVSODWLQȕ-cyclodextrin and CB[6] were bought 
from Sigma-Aldrich. Cucurbit[7]uril was bought from Dr Anthony Day, University of New 
South Wales, Australia. Motor2 was synthesised as previously described.12  
 
Electrophysiological Recordings from Mouse Sciatic Nerve (Neurotoxicity) 
BALB/C mice weighing between 25-30 g were euthanised with CO2. The sciatic nerve was 
carefully dissected from the knee to where it meets the spinal cord (3-5 cm in length) and 
immersed in HEPES-based physiological salt solution of the following composition: 150 mM 
NaCl, 5.4 mM KCl, 10 mM HEPES, 12 mM NaHCO3, 0.4 mM KH2PO4, 1.2 mM MgCl2, 2.5 
mM CaCl2, 10 mM glucose, pH 7.4. The sciatic nerve was then de-sheathed under a stereo-
microscope and laid across three inter-connecting chambers with ~ 70% of the nerve coiled in 
the middle chamber. The three chambers were filled with HEPES-based physiological salt 
solution to cover the nerve and electrical isolation between the three chambers was achieved 
with Vaseline. Electrical connections were made from the central chamber to one end 
chamber by means of Ag/AgCl electrodes. The remaining third chamber contained two 
platinum electrodes connected to a pulse generator. The middle chamber was connected to 
electrical grounds and the voltage from the third chamber was measured by a high input 
resistance amplifier. Electrical impulses were supplied to the nerve by a Grass S88 stimulator 
(0.4 Hz, 0.05 ms duration, 30V) via a SIU 5A stimulus isolation unit (Grass Instrument Co. 
Quincy, MA, USA). Signals were amplified with a CED 1902 transducer (Cambridge 
Electronic Design, Cambridge, England), digitised with an analogue digital converter 
(DigiData 1200 Interface, Axon Instruments, Scotland), and analysed using Microsoft 
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windows-based computer electrophysiological analysis software (WinWCP version 4.5.7; 
Dempster, 1988).   
 
All experiments were carried out at room temperature and prior to the beginning of each 
experiment the sciatic nerve was incubated in HEPES-based physiological salt buffer for 30 
min under constant super-maximal stimulation to demonstrate viability and consistency in the 
action potential recordings. If the action potential amplitude decreased by 10% the 
preparation was either remounted in fresh Vaseline or discarded.  Compounds were added to 
the middle chamber (1 mM of CB[6], CB[7], Motor2ȕ-cyclodextrin, cisplatin and 
cisplatin@CB[7]). At the end of each experiment tetrodotoxin (TTX; 1 µg/mL) was added to 
the central chamber in order to determine the extent of de-sheathing. Sciatic nerves with 
adequate de-sheathing show a rapid decrease in the amplitude of their action potential when 
treated with TTX. If the sciatic nerve was not adequately de-sheathed the response to TTX is 
not as rapid and the results for these nerves were not used in the data analysis. Measurements 
are expressed as the mean ± SEM (n = 3). 
 
Isolated Chick Biventer Cervicis Nerve Muscle Preparation (Myotoxicity) 
Chicks 3-15 days old were euthanised with CO2.  The back of their neck was plucked and the 
skin incised along the midline from the skull to below the base of the neck exposing both of 
the biventer cervicis muscle lying on either side of the midline. A thread was tied round the 
upper tendon muscle and a loop was tied at the bottom end of the neck muscle. The muscle 
was then cut away and kept in buffer solution of the following Krebs-Henseleit physiological 
salt solution: 118 mM NaCl, 25 mM NaHCO3, 11 mM glucose, 4.7 mM KCl, 1.2 mM 
MgSO4, 0.3 mM KH2PO4, 2.5 mM CaCl2 and equilibrated with a gas mixture of 95% O2, 5% 
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CO2 to maintain a pH of 7.4. The loop was used to attach the preparation in the organ bath 
and ring electrodes were placed around the tendon to stimulate the muscle indirectly.  
 
Prior to the addition of test compound, two control compound responses were obtained: 1 
mM acetylcholine (ACh, 30 s) and 30 mM KCl (30 s). These control compounds were then 
washed by over flow with Krebs-Henseleit solution. After the KCl response was obtained, the 
preparations were allowed to equilibrate for 30 min before the addition of 300 µM of 
compound (CB[6], CB[7], Motor2ȕ-cyclodextrin, cisplatin and cisplatin@CB[7]). At the 
end of the experiment, the two control responses were repeated to determine the change in 
postsynaptic activity. Measurements are expressed as the mean ± SEM (n = 3-8). 
 
Contractile Recordings from Rat Atria (Cardiotoxicity) 
Male Sprague Dawley rats weighing between 250-350 g were killed by cervical dislocation 
and their heart was dissected and maintained in cold Krebs-Henseleit physiological salt 
solution and equilibrated with a gas mixture of 95% O2/5% CO2 to maintain the pH at 7.4.  
The left and right atria were carefully removed from the heart under a stereo-microscope and 
a small loop was tied at one end of both atria and a knot at the other end using a thin thread. 
The atria were then mounted into separate 10 mL organ baths containing Krebs-Henseleit 
physiological salt solution, maintained at 37 ºC and gassed with 95% O2/5% CO2 throughout 
the experiment. In the organ bath, one end of the atria was tied to a metal rod and the other 
end was attached, via a cotton thread, to a Grass force displacement transducer model FT03 
connected to a powerlab/4SP analogue-to-digital recording system (AD Instruments) and 
displayed on a computer running Windows XP.   
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The right atria beats spontaneously due to the sinoatrial node, and a contraction was 
electrically evoked in the left atria by field stimulation (4 Hz, 2 ms duration, 10-15 V 
strength:  Grass S88). A resting tension of 0.5 g was applied to both the left and right atria 
and maintained throughout the experiment. Prior to the start of each experiment, 10 µM 
noradrenaline (NA) was added to the organ bath, and tissue that did not respond was 
discarded. With the tissue that did respond, the NA was washed out and the atria allowed to 
equilibrate for 30 min before the addition of test compound (300 µM of CB[6], CB[7], 
Motor2ȕ-cyclodextrin, cisplatin and cisplatin@CB[7]). Measurements are expressed as the 
mean ± SEM (n = 3-5). 
 
Results and Discussion  
The safe dose of cucurbiturils in animals is dependent on the size and type of the cucurbituril 
and its method of administration. The lowest maximum tolerated dose for CB[7] is 250 
mg/kg when administered by injection. Assuming a model human size of 75 kg, then this 
equates to a concentration of approximately 3.2 mM. Therefore, in this study we have 
examined the toxicity of three different cucurbiturils (CB[6], CB[7] and Motor2) at a 1/3 and 
1/10 of this maximum dose, giving 1 P0DQGȝ0VROXWLRQconcentrations, respectively, 
To put the cucurbituril toxicity results into perspective they are compared with the known 
VDIHPDFURF\FOHȕ-cyclodextrin, which has no reported neuro-, myo- or cardiotoxic side-
effects.  
 
Neurotoxicity    
A desheathed mouse sciatic nerve preparation was chosen as a model to study the 
neurotoxicity of the macrocycles. The desheathing process involved the careful removal of 
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the outer epineurium tissue that surrounds the nerve, thus allowing direct access to the nerve 
cells by the macrocycles.  
 
 
 
 
 
 
 
 
 
 
Figure 2. The change in the amplitude of the nCAP of untreated sciatic nerves over a period 
of two hours. At 80 minutes, the nerves have only lost 5% of their normal conductance (n = 
3). 
 
The natural drop-off in nerve conduction was evaluated using a time control study that 
monitored the stability of the electrically generated nerve compound action potential (nCAP) 
over a period of two hours.  Figure 2 shows that within the first 40 min the sciatic nerve 
preparations are still 100% viable with no change in the amplitude of the nCAP. By 80 
minutes the amplitude of the nCAP has decreased by only 5% ± 3.3 but by 120 minutes the 
sciatic nerve has lost 10% ± 4.2 of its viability.  As a result, the toxicity experiments were 
carried using macrocycle solutions of 1 mM over a period of 80 minutes to ensure reliability 
of the results.  
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Figure 3.  The change in nCAP amplitude of the sciatic nerve after treatment with (blue) 
CB[6] (p = 0.3), (red) CB[7] (p = 0.7) , (green) Motor2 (p = 0.1) DQGSXUSOHȕ-cyclodextrin 
(p = 0.1) after 80 minutes.   
 
The results show that CB[7] and Motor2 induced a decrease in nCAP amplitude by 4% ± 0.2 
and 13% UHVSHFWLYHO\ZKLOH&%>@DQGȕ-cyclodextrin induced an increase in nCAP by 
3% ± 4.6 and 7% ± 4.2, respectively (Figure 3)ȕ-cyclodextrin is not known to be neurotoxic, 
so the similar increase in nCAP by CB[6] implies that the cucurbituril is probably not 
neurotoxic. The decrease in nCAP by CB[7] is the same magnitude as the natural drop-off in 
untreated samples indicating it is also not neurotoxic. Whilst Motor2 decreased nCAP by 
13% there is no statistical difference (students paired t-test, p = 0.1) compared with untreated 
nerve. As such, all three cucurbiturils appear to display no neurotoxicity.  
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Effect of CB[7] on the Neurotoxicity of Cisplatin  
Neurotoxicity is one of the major dose limiting side effects of cisplatin. Studies have shown 
that cisplatin primarily accumulates in the dorsal root ganglia (DRG) of neurons and 
predominantly induces sensory neuropathy characterised by severe loss of proprioception 
(body movement), sensation of pins and needles, and numbness of the feet.21-23 
 
The effect of CB[7] on the neurotoxicity of cisplatin was investigated by analysing and 
comparing the effect of 1 mM cisplatin and cisplatin@CB[7] on the amplitude of nCAP.  
 
 
 
 
 
 
 
 
Figure 4. The difference in the change of nCAP amplitude of the sciatic nerve after treatment 
with 1 mM of (blue) free cisplatin (p = 0.3) and (red) cisplatin@CB[7] (p = 0.1).  
 
The results show there is no statistical difference in the neurotoxicity of cisplatin compared 
with cisplatin@CB[7] (Figure 4). At 80 min, cisplatin reduced the nCAP amplitude by 13% ± 
4.7, which shows some neurotoxicity but not at the level normally observed in the clinic. The 
reason for the lower toxicity is most likely because the sciatic nerve is composed mainly of 
neuronal axons with smaller amounts of DRG, which are predominantly located in the spinal 
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cord). Therefore, the small neurotoxicity caused by cisplatin in this experiment is due to the 
small amounts of DRG.  
 
The results for cisplatin@CB[7] are similar to free cisplatin with a decrease in nCAP 
amplitude of 22.7% ± 6.6. The results therefore indicate that CB[7] does not have a neuro-
protective effect for cisplatin. 
Myotoxicity  
The myotoxic activity of the macrocycles was examined using the isolated chick biventer 
cervicis nerve-muscle preparation. Under ex vivo conditions the muscle can be forced to 
contract using chemical or electrical stimulation. For chemical stimulation, the addition of 
exogenous acetylcholine (ACh) or KCl results in muscle contraction. The ACh acts by 
binding to nicotinic receptors located on the muscle membrane causing depolarisation 
followed by contraction (post-synaptic effect). Potassium chloride causes muscle membrane 
depolarisation resulting in calcium release into the synaptic cleft (the area between nerve and 
muscle). The calcium then binds to neuronal receptors which results in the release of ACh 
from the neuron ultimately causing muscle contraction (pre-synaptic effect).   
 
Baseline results for the force of muscle contraction was determined using both electrical and 
chemical stimulation. The nerve-muscle was then exposed to the macrocycles and after two 
hours the force of muscle contraction was again determined (Figure 5). The macrocycles are 
myotoxic if they demonstrate a statistically significant increase or reduction in the force of 
muscle contraction compared with baseline results. An increase in force of contraction due to 
exogenous ACh indicates that the compound tested may have anticholinesterase effect; 
cholinesterase is an enzyme located in the synaptic cleft that terminates signal transmission 
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by breaking down acetylcholine activity therefore prolonging/increasing the effect of ACh. 
An increase in the lifetime of ACh will synergistically increase/prolong the response to KCl. 
 
 
 
 
 
 
 
 
  
 
 
 
Figure 5. The nerve-PXVFOH¶VUHVSRQVHVWRJUH\$&KJUHHQ.&ODQGSXUSOHWKe 
electrically stimulated contraction at two hours after exposure to macrocycle for untreated 
nerves (n = 3), &%>@Q &%>@Q 0RWRUQ DQGȕ-cyclodextrin (n = 3).  
 
After two hours, the untreated nerve-muscle¶VUHVSRQVHWR$&K, KCl and its electrically 
stimulated contraction had all decreased by 4% ± 2, 18% ± 5 and 11% ± 5, respectively. 
Cucurbit[6]uril increased nerve-muscle response to ACh by 10% ± 10, and decreased its 
response to KCl and electrical stimulated contraction by 24% ± 17 and 20% ± 4, respectively. 
Cucurbit[7]uril decreased the nerve-musclH¶VUHVSRQVHWR$&K.&ODQG the electrically 
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stimulated contraction by 21% ± 10, 51.8% ± 8 and 84% ± 9, respectively. The cucurbituril-
derivative, Motor2, increased nerve-muscle response to both ACh and KCl by (37% ± 12) 
and (2% ± 12), respectively, and decreased its electrically stimulated contraction by 15% ± 
13. ȕ-cyclodextrin increased nerve-muscle response to ACh by 20% ± 7, decreased its 
response to KCl by 15% ± 9, and increased its electrical stimulated contraction by 11% ± 10.   
Overall the largest myotoxic effect was observed after nerve-muscle exposure to CB[7]. 
Significant decreases in activity are apparent for KCl (p = 0.05) and electrical stimulation (p 
= 0.01), this indicates that CB[7] may be binding to and blocking the SRVWV\QDSWLFPXVFOH¶V
nicotinic receptors and therefore interfering with the depolarisation ability of the membrane. 
A small decrease in twitch via electrical stimulation is also observed after exposure to CB[6] 
(p = 0.3) although the decrease is considerably smaller in magnitude compared with CB[7]. 
*LYHQWKDWȕ-cyclodextrin also results in a decrease of electrically stimulated contraction (p = 
0.9), it is not a known myotoxic compound, the results may suggest that the electrical 
stimulation results for CB[6] and CB[7] are statistically decreased, however this may not 
result in in vivo toxicity. 
 
Effect of CB[7] on the Myotoxicity of Cisplatin  
The effect of CB[7] on the myotoxicity of cisplatin was investigated by analysing and 
comparing the effect of cisplatin and cisplatin@CB[7] on the response of the nerve-muscle¶V
chemical and electrical stimulation. 
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Figure 6.  The effect of cisplatin (n = 4) and cisplatin@CB[7] (n = 8) on the nerve-PXVFOH¶V
response to (grey) ACh, (green) KCl and (purple) the amplitude of its electrically stimulated 
contraction after two hours of exposure to drug.  
 
The results show that cisplatin induced significant myotoxic activity when measured using 
both chemical and electrical stimulation (Figure 6). Free cisplatin increased nerve-muscle 
contraction force to ACh and KCl by (96% ± 32, p = 0.005) and (121% ± 3, p = 0.001), 
respectively, and decreased the force of its electrically stimulated contraction by 96% ± 4 (p 
= 0.001) which is consistent with the peripheral neuropathy known to occur with cisplatin 
chemotherapy. The results also suggest that cisplatin may have anticholinesterase activity as 
demonstrated in previous studies and that this may also contribute in part to the neurotoxic 
side effects of cisplatin.24  Encapsulation of cisplatin by CB[7] decreased nerve-muscle 
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response to ACh by 17% ± 6 (p = 0.4), and increased its response to KCl by 59% ± 27 (p = 
0.2). Cucurbit[7]uril showed a myo-protective effect as cisplatin@CB[7] decreased the 
electrical stimulated muscle contraction by only 36%  ± 12 (p = 0.04) only; this is a reduction 
of the myotoxic activity of free cisplatin by 60%.  
 
 
Cardiotoxicity 
Heart atria from rats were used as a model to study the cardiotoxic activity of the 
macrocycles. The right atrium contains a natural pacemaker called the sinoatrial (SA) node 
which causes the atrium to contract naturally; however, such a pacemaker is absent in the left 
atrium and electrical stimulation is needed to initiate contraction. 
 Both atria were treated with each of the four macrocycles for a period of two hours. The 
function of the atria was studied by monitoring both the rate of atria contraction (BPM, beats 
per minute) and force of contraction (amplitude of contraction). 
 19 
Figure 6. The change in atria contraction rate (top panel) and force of contraction (bottom 
panel) in untreated right (dark red, dark blue) and left atria (light red, light blue) over a period 
of two hours.  
 
In the untreated atria (control), the results show that by the end of the experiment the left 
atrium was more stable than the right as no changes were observed in either its rate or force 
of contraction (Figure 6). In contrast, after two hours the rate and force of right atrium 
contraction had increased by 8% ± 1 and 16% ± 1.9, respectively.  
 
The cardiotoxicity results show that each cucurbituril portrayed significant cardiotoxic 
activity with Motor2 being the most cardiotoxic. All of the macrocycles induced greater 
changes in the force of contraction compared with the contraction rate.  Changes in the force 
of contraction are seen within the first 15-30 minutes after exposure to macrocycle, whereas a 
longer period of time (30-45 minutes) is required before changes in the rate of contraction are 
observed (Figure 7). 
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Table 1. A summary of the cardiotoxic changes induced by each macrocycle on the rate and 
force of both right and left atria contraction. The positive and negative signs indicate an 
increase or decrease in rate and force of contraction, respectively. The statistical significance 
RIHDFKUHVXOWLVJLYHQSVFRUHEDVHGRQVWXGHQW¶VSDLUHGW-test). 
Macrocycle 
(ȝ0 
Percent change in rate of 
contraction 
Percent change in force of 
contraction 
Right atrium Left atrium Right atrium Left atrium 
 
CB[6] 
+12 ± 6 
(p = 0.3) 
+3.3 ± 1 
(p = 0.3) 
-41.7 ± 19.7 
(p = 0.06) 
-55  ± 6.1 
(p = 0.06) 
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CB[7] 
+31 ± 13.6 
(p = 0.2) 
-10 ± 3.5 
(p = 0.4) 
 
-29 ± 3.4 
(p = 0.02) 
 
-18  ± 6.8 
(p = 0.3) 
 
Motor2 
+30 ± 19 
(p = 0.4) 
+15 ± 3.8 
(p = 0.2) 
 
-68 ± 3.1 
(p = 0.001) 
 
-60 ± 5.4 
(p = 0.008) 
 
ȕ-cyclodextrin +32 ± 12 
(p = 0.2) 
+3 ± 3 
(p = 0.5) 
+1 ± 3.3 
(p = 0.09) 
-33 ± 4.1 
(p = 0.04) 
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Figure 7. The changes in the rate and force of contraction in both the right (dark red, dark 
blue) and left atria (light red, light blue) when treated ZLWKȝ0RID&%>@E&%>@
(c) Motor2 or Gȕ-cyclodextrin over a period of two hours. 
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Effect of CB[7] on the Cardiotoxicity of Cisplatin   
Although uncommon, there are various clinical studies that have reported cardiotoxic effects 
of cisplatin. Toxicity occurs in the form of atrial or ventricular arrhythmias, tachycardia, 
bradycardia and conduction abnormalities. Most of these cardiac problems are reported to be 
clinically silent and occurring within hours of drug infusion.25-27 
 
The protective effect of CB[7] on the cardiotoxic activity of cisplatin was investigated using 
free cisplatin and cisplatin@CB[7] in the unpaced right atrium. The right atrium was chosen 
for this study as cisplatin exhibited no cardiotoxic activity in the left paced atrium (data not 
shown).  
 
 
 
 
 
 
 
 
 
 
 
Figure 8. The effects of (blue) cisplatin and (red) cisplatin@CB[7] on right atria contraction 
rate (top panel) and force of contraction (bottom panel) over a period of two hours. 
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The results show that cisplatin induced cardiotoxic activity by reducing both the rate and 
force of contraction by 68.8% ± 8.4 (p = 0.07) and 53.7% ± 17.0 (p= 0.2), respectively 
(Figure 8). )XUWKHUPRUHFLVSODWLQLQGXFHGDJUDGXDODQGGUDPDWLFLQFUHDVHLQWKHDWULD¶VIRUFH
of contraction by 250% within the first 60 min, after which it was reduced by 54% by the end 
of the experiment. When encapsulated by CB[7], the cardiotoxic activity of cisplatin was 
significantly reduced; cisplatin@CB[7] induced only an 11% ± 5.6 (p = 0.2) decrease in the 
rate of atria contraction, and increased the force of contraction by only 27% ± 18.0 (p = 0.2). 
As well as reducing the magnitude of change in rate of contraction, CB[7] also stabilised the 
force of contraction compared to free cisplatin. After 60 min the force of contraction 
increased by just 27% ± 18.0 and was maintained at this magnitude throughout the 
experiment. 
 
Conclusion 
In this study, the cucurbituril macrocycles CB[6] and CB[7] and their derivative, Motor2, 
were tested for their neuro-, myo- and cardiotoxic activity and the results compared with the 
NQRZQVDIHȕ-cyclodextrin using ex vivo models.  
The results show that all of the macrocycles showed no neurotoxic activity within the time 
frame tested as there was no statistically measurable difference between the changes in nCAP 
induced by the cucurbiturils compared to that caused by ȕ-cyclodextrin or control. In the 
myotoxicity study, CB[7] showed the greatest myotoxic activity by causing the greatest 
reduction in the electrically stimulated nerve-muscle contraction, whilst Motor2 DQGȕ-
cyclodextrin displayed the least myotoxic activity. All of the macrocycles showed cardiotoxic 
activity by predominantly reducing the force of atria contraction compared to changes in the 
rate of its contraction, with Motor2 being the most cardiotoxic.  
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The effect of drug encapsulation by CB[7] on these specific tissue toxicities was tested using 
the platinum-based anticancer drug cisplatin. While free cisplatin displayed toxicity to all 
three tissue types, when encapsulated by CB[7], the extent of its myo- and cardiotoxic 
activity were significantly reduced while no statistical change in toxicity was seen in the 
neurotoxicity studies. These ex vivo results are consistent with the lack of acute systemic 
toxicity seen by for CB[n]s when previously tested for their in vitro and in vivo systemic 
toxicities and also show the advantages of using CB[7] as a drug delivery vehicle in 
providing protection from some of the side effects associated with the platinum-based drugs.  
 
Overall, whilst some toxicity of the macrocycles was observed for myo- and cardio toxicity, 
these experiments represent very high doses with direct access to the tissues. In a human 
clinical setting, the dose used will be 2- to 10-fold lower. For example, if used as a protective 
agent for cisplatin then the actual dose of CB[7] will be 80 to 160 µM (assuming a cisplatin 
dose of 60 to 120 mg/m2).28 From this much of the dose will be quickly cleared via the 
kidneys and the dose to which the nerves, muscle and heart will be exposed will be 
significantly lower still. The results, however, do warrant further investigation into the 
toxicity of CB[n]s to establish their safety. 
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